Ligand Pharmaceuticals (LGND) EBT (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted EBT of -$24.3 million for Q1 2026, down 142.72% sequentially from $56.8 million in Q4 2025, and up 51.66% YoY from -$16.0 million in Q1 2025.
Ligand Pharmaceuticals (LGND) EBT (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported EBT for 17 years, with the latest figure at -$24.3 million in Q1 2026.
- Quarterly EBT rose 51.66% year-over-year to -$24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 214.76% YoY) and the FY2025 annual result came in at $159.0 million, up 6212.95% from the prior year.
- EBT eased to -$24.3 million in Q1 2026 per LGND's latest filing, from $56.8 million in the prior quarter.
- Over five years, EBT peaked at $141.1 million in Q3 2025 and troughed at -$65.4 million in Q2 2024.
- A 5-year average of $13.9 million and a median of $8.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT slumped 2162.13% in 2024, then jumped 2326.49% in 2025.
- Over 5 years, EBT stood at $24.1 million in 2022, then dropped by 29.18% to $17.1 million in 2023, then slumped by 329.28% to -$39.2 million in 2024, then surged by 244.85% to $56.8 million in 2025, then slumped by 142.72% to -$24.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$24.3 million, $56.8 million, and $141.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 64.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.30 Mn |
| Mar 31, 2026 | -24.26 Mn |
| Dec 31, 2025 | 56.78 Mn |
| Sep 30, 2025 | 141.14 Mn |
| Jun 30, 2025 | 11.22 Mn |
| Mar 31, 2025 | -50.18 Mn |
| Dec 31, 2024 | -39.20 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -65.39 Mn |
| Mar 31, 2024 | 113.45 Mn |
| Dec 31, 2023 | 17.10 Mn |
| Sep 30, 2023 | -12.14 Mn |
| Jun 30, 2023 | 3.17 Mn |
| Mar 31, 2023 | 55.54 Mn |
| Dec 31, 2022 | 24.14 Mn |
| Sep 30, 2022 | 12.35 Mn |
| Jun 30, 2022 | 8.66 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | 17.88 Mn |
| Sep 30, 2021 | 15.26 Mn |